PROCEPT BioRobotics Reports Strong 37% Revenue Growth, Improved Margins, and Key Reimbursement Upgrade in 2025 Annual Report
Summary
PROCEPT BioRobotics reported strong 37% revenue growth and improved gross margins for fiscal year 2025, alongside a significant upgrade to a Category I CPT code for its Aquablation therapy, enhancing future reimbursement prospects despite continued net losses.
Key Events
-
Strong Full-Year Revenue Growth
The company reported $308.1 million in revenue for fiscal year 2025, representing a substantial 37% increase compared to $224.5 million in 2024.
-
Improved Gross Margin
Gross margin increased to 64% in 2025, up from 61% in 2024, indicating enhanced operational efficiency and scale.
-
Continued Net Losses
PROCEPT BioRobotics incurred a net loss of $95.6 million in 2025, a slight increase from $91.4 million in 2024, as the company continues to invest in growth and development.
-
Significant Reimbursement Upgrade
Aquablation therapy was assigned a new Category I CPT code (52597), effective January 1, 2026, replacing the prior Category III code. This is a major positive for future reimbursement and broader market acceptance.
Analysis
PROCEPT BioRobotics' 2025 annual report confirms robust operational performance with significant revenue growth and improved gross margins. The upgrade of Aquablation therapy to a Category I CPT code, effective January 1, 2026, is a critical development that is expected to substantially enhance future reimbursement and market adoption. While the company continues to incur net losses, this is typical for a growth-stage medical technology firm, and the reported liquidity provides sufficient runway for the next 12 months. This filing provides the audited details following the preliminary Q4 and full-year results likely announced in a recent 8-K, and reinforces the strategic direction discussed at the Investor Day.
At the time of this filing, PRCT was trading at $23.63 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $19.35 to $70.80. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.